GlassScriptPhysician profile
Faisal Sheikh
NPI 1114188000
$5,557.95
in general payments reported to CMS, 2019-2025
26 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $730 · 2021: $660 · 2022: $751 · 2023: $787 · 2024: $811 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $1,174.44 | 2022-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Abbvie INC. | $1,054.50 | 2019-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $682.95 | 2019-2025 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $434.27 | 2019-2022 | |
| Novo Nordisk INC | $339.44 | 2024 | Wegovy |
| Olympus America INC. | $226.89 | 2023 | Evis Exera Lll Colonovideoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $209.40 | 2019-2022 | |
| Ardelyx, INC. | $181.97 | 2023-2024 | Ibsrela |
| Enterra Medical, INC. | $176.26 | 2024-2025 | |
| Genzyme Corporation | $155.76 | 2025 | |
| Madrigal Pharmaceuticals | $144.23 | 2025 | Rezdiffra |
| Dova Pharmaceuticals | $131.03 | 2019 | |
| Pfizer INC. | $123.88 | 2025 | |
| Braintree Laboratories, INC. | $93.20 | 2019-2023 | Sutab |
| Evoke Pharma, INC. | $80.94 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $55.12 | 2020-2025 | Sucraid |
| Redhill Biopharma INC. | $54.09 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $52.40 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $46.88 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $25.14 | 2025 | Zenpep |
| Concordia Pharmaceuticals INC. | $21.87 | 2019 | |
| Valinor Pharma, LLC | $20.09 | 2023 | Movantik |
| Daiichi Sankyo INC. | $19.48 | 2021 | |
| Pharmacosmos Therapeutics INC. | $18.65 | 2023 | Monoferric |
| Endo Pharmaceuticals INC. | $17.54 | 2019 | |
| Janssen Biotech, INC. | $17.53 | 2023 | Simponi, Simponi Aria, Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.